Objectives: The activity of ceftazidime/avibactam was assessed against 24 750 isolates of Enterobacteriaceae collected from 96 medical centres in 18 European countries as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme from 2012 to 2015. Activity was analysed against subsets of isolates based on resistant phenotypes and b-lactamase content.
Introduction
Antimicrobial resistance is a growing problem in Europe and around the globe. The European Antimicrobial Resistance Surveillance Network (EARS-Net) reported that the percentages of invasive Escherichia coli and Klebsiella pneumoniae isolates resistant to third-generation cephalosporins, those additionally resistant to fluoroquinolones and aminoglycosides, and K. pneumoniae resistant to carbapenems increased significantly between 2012 and 2015. 1 The European Survey of Carbapenemase-Producing Enterobacteriaceae documented an increase in carbapenemaseproducing Enterobacteriaceae between 2013 and 2015 and a worsening epidemiological situation in several countries. 2 Use of the last-line antimicrobials colistin and fosfomycin to treat infections caused by carbapenemase-producing Enterobacteriaceae has selected for resistance among carbapenemase-positive K. pneumoniae. 3 Future outbreaks of XDR and pandrug-resistant Enterobacteriaceae in Europe are considered likely. 2 Avibactam is a non-b-lactam b-lactamase inhibitor with in vitro activity against Ambler class A, class C and some class D b-lactamases. 4, 5 The combination of ceftazidime with avibactam has demonstrated potent in vitro activity against serine b-lactamase-producing Enterobacteriaceae that do not harbour class B MBLs, including ESBL-positive, AmpC-positive, carbapenemase-positive and carbapenemase-negative carbapenem-non-susceptible isolates with altered outer membrane permeability, as well as colistin-resistant carbapenemase-producing Enterobacteriaceae. [6] [7] [8] [9] [10] [11] Reduced susceptibility to ceftazidime/avibactam is predominantly conferred by MBL production 4 or sequence alterations in target proteins. [12] [13] [14] [15] [16] Additional resistance mechanisms also play a role in some cases. 17, 18 Ceftazidime/avibactam was recently approved in the EU for the treatment of adult 
Materials and methods
Isolate collection, antimicrobial susceptibility testing and screening for b-lactamase genes are described in the Supplementary data (available as Supplementary data at JAC Online).
Results
Of the 24 750 Enterobacteriaceae isolates collected, 99.4% were susceptible to ceftazidime/avibactam (MICs 8 mg/L; MIC 90 " 0.5 mg/L), compared with susceptibility of 92.1%-97.2% for carbapenems and amikacin and ,84% for other tested agents including ceftazidime (Table 1) . Ceftazidime/avibactam MIC 90 values against individual species and species groups of Enterobacteriaceae were 0.12-1 mg/L, with 98.6%-99.9% of the isolates being susceptible ( Table 1 ). The in vitro activity of ceftazidime/avibactam was increased against isolates that did not carry MBLs, with 99.9% testing as susceptible and the susceptibility of individual species increasing to 99.8%-100% (Table 1 and Table S1 ). As expected, ceftazidime/avibactam was not active against MBLpositive Enterobacteriaceae (MIC 90 .128 mg/L; 9.2% susceptible), with only colistin retaining good activity against these isolates (MIC 90 " 2 mg/L; 90.3% susceptible) ( Table 1) . Percentages of susceptibility to ceftazidime/avibactam ranged from 99.2% to 100% (MIC 90 " 0.25-0.5 mg/L) among all countries surveyed except Romania (96.3% susceptible, MIC 90 " 1 mg/L) and Greece (96.4% susceptible, MIC 90 " 1 mg/L) ( Figure 1 and Tables S2 to S19). For these two countries, susceptibility increased to 99.9% and 99.7%, respectively, when MBL-positive isolates were excluded (Tables S8  and S14 ).
The distribution of b-lactamases among molecularly characterized isolates from each country is described in Tables S20 to S37 . CTX-M-type ESBLs predominated in all countries except Greece, with CTX-M-15 composing 50% or greater of the detected ESBLs, while SHV-type ESBLs predominated in Greece. TEM-, VEB-, PERand GES-type ESBLs were rare ( Figure S1 ). The prevalence of AmpC cephalosporinases varied by country, with CMY-and DHA-type enzymes found most frequently ( Figure S2 ). The prevalence of carbapenemases also varied, with OXA-48-like, KPC-type, VIM-type, NDM-type and GES-type carbapenemases detected in 12, 10, 9, 7 and 2 countries, respectively ( Figure S3 ). The highest percentages of MBL-positive isolates were identified among Enterobacteriaceae collected in Greece (3.5%) and Romania (3.6%), whereas MBLpositive isolates represented ,1.0% of isolates collected in other countries (Tables S2 to S19). No carbapenemases were detected in isolates from Sweden or the Netherlands and no isolates carrying IMP-type MBLs were detected in any country. Ceftazidime/avibactam was very active against the majority of carbapenemasenegative isolates, with 98.3%-100% of isolates carrying ESBLs, AmpCs, broad-spectrum or inhibitor-resistant SHV-and TEM-type enzymes and combinations thereof testing as susceptible (MIC 90 values ranging from 0.5 to 2 mg/L) (Table S38 ). Ceftazidime/avibactam demonstrated good activity against isolates carrying KPC (MIC 90 " 4 mg/L; 98.9% susceptible; 1.5% of collected isolates), GES (MICs 0.5-1 mg/L; 100% susceptible; 0.02% of collected isolates) and OXA-48-like (MIC 90 " 2 mg/L; 99.2% susceptible; 1.1% of collected isolates) carbapenemases. Ceftazidime/avibactam displayed no activity against MBL-positive Enterobacteriaceae (0.5% of collected isolates), with only 12 isolates presumed to produce the carbapenemase in low quantity, testing with MICs 8 mg/L (Table S38 ).
The in vitro activity of ceftazidime/avibactam and comparators was assessed against Enterobacteriaceae isolates that were nonsusceptible to currently used antimicrobials, including ceftazidimenon-susceptible (25.2% of collected isolates), meropenem-nonsusceptible (2.8% of collected isolates), colistin-resistant (1.3% of collected isolates, excluding isolates of Proteeae and Serratia spp.) and MDR (16.1% of collected isolates) subsets (Tables S39 to S42) . Overall, 97.7% of ceftazidime-non-susceptible isolates were susceptible to ceftazidime/avibactam, compared with 81.4%-89.1% susceptibility to carbapenems, colistin and tigecycline (Table S39) . Across the region, the percentage of ceftazidime-non-susceptible isolates ranged from 7.9% to 50.2% ( Figure S4 ). Greater than 97% of ceftazidime-non-susceptible isolates remained susceptible to ceftazidime/avibactam for all countries except Greece (86.0% susceptible) and Romania (89.3% susceptible), where the activity of ceftazidime/avibactam was increased by 12.8% and 10.3%, respectively, against ceftazidime-non-susceptible MBL-negative isolates (Tables S8 and S14) .
Ceftazidime/avibactam displayed reduced activity (83.3% susceptible) against meropenem-non-susceptible Enterobacteriaceae that nevertheless exceeded the activity of other tested comparators, including tigecycline and colistin (0.4%-74.1% susceptible) (Table S40 ). The MIC 90 values of ceftazidime/avibactam against all meropenem-non-susceptible isolates and isolates of individual species were 128 to .128 mg/L; however, MIC 90 values were decreased 16-to .64-fold against the corresponding MBLnegative, meropenem-non-susceptible subsets, yielding susceptibilities of 85.7%-100% depending on the species. The percentages of meropenem-non-susceptible isolates ranged from 0% to 14.2% among countries ( Figure S5 ). Ceftazidime/avibactam displayed good activity in countries where meropenem non-susceptibility was primarily conferred by production of serine b-lactamases (Belgium, the Czech Republic, Italy, Portugal, Russia and Turkey), but activity was reduced in countries with an elevated proportion of MBLs amongst the carbapenemases (Hungary, the UK, Greece and Romania) (Tables S3, S4 , S8, S9, S10, S13, S14, S15, S18 and S19, and Figure S3 ).
Ceftazidime/avibactam was active against 98.2% of colistinresistant isolates overall and was superior to tested comparators (30.8%-81.0% susceptible). Although percentages of colistin resistance ranged from 0.2% to 4.3% ( Figure S6 ), susceptibility to ceftazidime/avibactam was .96% for isolates from all countries except Belgium (87.5% susceptible) and the UK (88.9% susceptible) (Tables S3 and S19 ). Only three colistin-resistant, MBL-positive isolates were identified and these were K. pneumoniae collected in Greece, Turkey and the UK that carried NDM-1.
Susceptibility Figure S7 ). Activity was reduced against MDR isolates collected in Greece (83.8% susceptible) and Romania (84.9% susceptible) and was increased by 14.8% and 14.6%, respectively, against the corresponding subsets of MBL-negative MDR isolates (Tables S8 and S14) . Ceftazidime/avibactam displayed comparable or superior activity to other agents tested, including carbapenems, colistin and tigecycline, against MDR isolates collected from individual countries and from the region as a whole (Tables S2 to S19 and S42) .
Discussion
Ceftazidime/avibactam demonstrated potent in vitro activity against Enterobacteriaceae isolates collected in Europe, including subsets of isolates that are non-susceptible to ceftazidime or meropenem, resistant to colistin or have an MDR phenotype. Ceftazidime/avibactam was active in vitro against 99.7% of molecularly characterized MBL-negative isolates carrying all combinations of class A, C and D b-lactamases, including carbapenemase-producing Enterobacteriaceae carrying KPC, GES or OXA-48-like enzymes, regardless of species or country of origin. The activity of ceftazidime/avibactam was adversely affected by the presence of class B MBLs. In addition, 14 isolates of Enterobacteriaceae (8 K. pneumoniae, 2 E. coli, 1 Enterobacter aerogenes, 1 Klebsiella oxytoca, 1 Providencia stuartii and 1 Serratia marcescens) that lacked the MBLs screened as part of this study tested as non-susceptible to ceftazidime/avibactam. These isolates were found in Italy, Russia, Belgium, Greece and Hungary, and may harbour known or as-yet-undefined resistance mechanisms. [12] [13] [14] 17 The observed distribution of ESBL and carbapenemase types was in general agreement with published reports. 2, 3, 20 The overall resistance patterns were similar to those reported by EARS-Net, with higher percentages of resistance primarily found in southern and eastern Europe.
1 Among countries included in both studies, the highest percentages of carbapenem-non-susceptible Enterobacteriaceae were observed in Italy, Greece and Romania. Enterobacter spp. included E. aerogenes (n " 971), E. asburiae (n " 141), E. cancerogenus (n " 1), E. cloacae (n " 1692), E. hormaechei (n " 1), E. kobei (n " 54) and E. ludwigii (n " 18).
e Citrobacter spp. included C. amalonaticus (n " 16), C. braakii (n " 92), C. diversus (n " 1), C. farmeri (n " 5), C. freundii (n " 744), C. koseri (n " 486), C. murliniae (n " 4), C. sedlakii (n " 7), C. youngae (n " 1) and Citrobacter, species unknown (n " 3).
f Proteeae included Morganella morganii (n " 701), Proteus hauseri (n " 3), Proteus mirabilis (n " 1592), Proteus penneri (n " 28), Proteus vulgaris (n " 829), Providencia alcalifaciens (n " 12), Providencia rettgeri (n " 101) and Providencia stuartii (n " 124). g Other Enterobacteriaceae included Escherichia fergusonii (n " 1), Escherichia hermannii (n " 1), Hafnia alvei (n " 4), Klebsiella variicola (n " 4), Pantoea agglomerans (n " 1), Pluralibacter gergoviae (n " 1), Raoultella ornithinolytica (n " 49), Raoultella planticola (n " 18), Raoultella terrigena (n " 2), Serratia liquefaciens (n " 11), Serratia marcescens (n " 584), Serratia odorifera (n " 1) and Serratia ureilytica (n " 4).
Good agreement was also observed for countries with the highest percentages of polymyxin-resistant (Greece and Italy) and MDR (Italy, Romania, Greece, Poland, Hungary and the Czech Republic) isolates. 1 High percentages of colistin-resistant (Turkey) and MDR (Russia and Turkey) Enterobacteriaceae were also found in countries not surveyed by EARS-Net. Differences in the activity of ceftazidime/avibactam were not observed across the different countries surveyed, with the exception of those countries that showed an elevated incidence of MBL-producing isolates.
Ceftazidime/avibactam provides a valuable alternative for treatment of infections caused by Enterobacteriaceae isolates resistant to many commonly used and last-line agents. However, country-and site-specific differences in the incidence of MBLmediated resistance must be taken into account when assessing the value of ceftazidime/avibactam for a particular setting.
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